Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay - 25/04/21
, Megan McIntosh a, Claire Atkinson a, Tabitha Mahungu b, Edward Wright c, Wendy Chatterton d, Michael Gandy d, Matthew B. Reeves a, ⁎
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | An ELISA based cPass assay provides a measure of Spike RBD binding antibodies. |
• | Binding in a cPass ELISA correlates strongly with pseudotyped virus neutralisation. |
• | ELISA-based surrogate assays provide rapid data on neutralising capacity. |
Abstract |
Objectives |
To assess whether a commercially available CE-IVD, ELISA-based surrogate neutralisation assay (cPass, Genscript) provides a genuine measure of SARS-CoV-2 neutralisation by human sera, and further to establish whether measuring responses against the RBD of S was a diagnostically useful proxy for responses against the whole S protein.
Methods |
Serum samples from 30 patients were assayed for anti-NP responses, for ‘neutralisation’ by the surrogate neutralisation assay and for neutralisation by SARS-CoV-2 S pseudotyped virus assays utilising two target cell lines. Correlation between assays was measured using linear regression.
Results |
The responses observed within the surrogate neutralisation assay demonstrated an extremely strong, highly significant positive correlation with those observed in both pseudotyped virus assays.
Conclusions |
The tested ELISA-based surrogate assay provides an immunologically useful measure of functional immune responses in a much quicker and highly automatable fashion. It also reinforces that detection of anti-RBD neutralising antibodies alone is a powerful measure of the capacity to neutralise viral infection.
Le texte complet de cet article est disponible en PDF.Plan
Vol 82 - N° 5
P. 170-177 - mai 2021 Retour au numéro
Article précédent
- Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers
- Ross J. Harris, Heather J. Whitaker, Nick J. Andrews, Felicity Aiano, Zahin Amin-Chowdhury, Jessica Flood, Ray Borrow, Ezra Linley, Shazaad Ahmad, Lorraine Stapley, Bassam Hallis, Gayatri Amirthalingam, Katja Höschler, Ben Parker, Alex Horsley, Timothy J.G. Brooks, Kevin E. Brown, Mary E. Ramsay, Shamez N. Ladhani
- IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression
- Emmanuel Tharmarajah, April Buazon, Vishit Patel, Jennifer R. Hannah, Maryam Adas, Victoria B. Allen, Katie Bechman, Benjamin D. Clarke, Deepak Nagra, Sam Norton, Mark D. Russell, Andrew I. Rutherford, Mark Yates, James B. Galloway
Bienvenue sur EM-consulte, la référence des professionnels de santé.